Author:
Anand Ajeeta,Aoyagi Hideki
Abstract
AbstractHyperphosphatemia is a secondary issue associated with chronic kidney disorder. Use of phosphate binders and dialysis are the treatments for hyperphosphatemia, albeit with harmful side effects and high cost, respectively. A safer and healthier approach is attempted to administer phosphate-accumulating organisms (PAOs) from probiotics to prevent hyperphosphatemia. However, screening and isolation of PAOs are limited by inefficient enrichment of relevant metabolism and contamination. Therefore, we devised a novel strategy to isolate elite PAOs from Lactobacillus casei JCM 1134 and Bifidobacterium adolescentis JCM 1275 (previously reported PAOs). PAOs were first enriched for phosphate uptake and incubated in low-pH phosphate-free media to dormant non-PAOs, and then purified using Percoll density gradient centrifugation. Subsequently, elite PAOs were isolated from centrifuged pellet on a toluidine blue O-supplemented agar-based media. Using this technique, elite PAOs could not only be isolated, but also semi-quantitatively scored for their phosphate accumulation capabilities. Additionally, these scores correlated well with their accumulated phosphate values. The elite PAOs isolated from L. casei and B. adolescentis showed 0.81 and 0.70 [mg-phosphate/mg-dry cell], respectively (23- and 4.34-fold increase, respectively). Thus, our method can be used to successfully isolate elite PAOs, which might be of use to prevent hyperphosphatemia at early stages.
Funder
Japan Society for the Promotion of Science London
Tojuro Iijima Foundation for Food Science and Technology
Sumitomo Electric Industries Group Corporate Social Responsibility Foundation
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Emmett, M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int. 66, S25–S32 (2004).
2. Block, G. A. et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15, 2208–2218 (2004).
3. National kidney foundation. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) - The National Kidney Foundation. Available at, https://www.kidney.org/professionals/guidelines. (Accessed: 1st February 2018).
4. Webster, A. C., Nagler, E. V., Morton, R. L. & Masson, P. Chronic Kidney Disease. Lancet 389, 1238–1252 (2017).
5. Lopes, A. A. et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Evaluation of possible confounding by nutritional status. Am. J. Kidney Dis. 60, 90–101 (2012).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献